Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treatment in first line of mantle cell lymphoma for patients under 66 Years by the VAD [vincristine + doxorubicin + dexamethasone] -chlorambucil -rituximab regimen followed by intensification and autologous PBSC [Peripheral blood stem cell] transplantation after marrow purging with rituximab

Trial Profile

Treatment in first line of mantle cell lymphoma for patients under 66 Years by the VAD [vincristine + doxorubicin + dexamethasone] -chlorambucil -rituximab regimen followed by intensification and autologous PBSC [Peripheral blood stem cell] transplantation after marrow purging with rituximab

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Apr 2016

At a glance

  • Drugs Rituximab (Primary) ; Chlorambucil; Dexamethasone; Doxorubicin; Vincristine
  • Indications Mantle-cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Feb 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
    • 31 Jul 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top